The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

31/03/2016 - 2 minutes

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology.

affimed_tandabs_bispecific_antibodies_cancerAffimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one from Germany).

The company closed 2015 with €76.7M – enough money to fund its pipeline until the beginning of 2018 (or at least this is the plan). Key fundraising events were the follow-on offering on the NASDAQ (after a troublesome IPO in 2014), which was brought in €33.5M. Aeris, a long-standing shareholder, also put in an additional €19.1M in October 2015.

From the operations side, Affimed made a strategic move in its expansion towards the US in June, illustrated by some key hirings. These include Caroline Stewart, former Wall Street executive, Oscar Kashala, experienced in oncology development,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member